Attention‐deficit hyperactivity symptoms and risk of alcohol use relapse
Neuropsychopharmacology Reports · 2023-03 · 43 (1) · 103-111
DOI: 10.1002/npr2.12312 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuropsychopharmacology Reports, online erschienen am 26.12.2022. Verfasst von Takahiro Kawata und 7 weiteren Autor:innen. Beteiligte Einrichtung: Liaison Psychiatry and Psycho-Oncology Unit, Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo …. Hauptthemen laut MEDLINE: Alcoholism. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
Aim
Alcohol use disorder (AUD) is frequently accompanied by comorbid attention‐deficit hyperactivity disorder (ADHD). Comorbid ADHD has been reported to increase the severity of AUD. We investigated whether ADHD severity also influences AUD relapse risk at baseline and after inpatient treatment.
Methods
In this study, 187 AUD patients admitted to Narimasu Kosei Hospital from October 2019 to March 2021 were included in the analysis. According to the Adult ADHD Self‐Report Scale (ASRS), participants were divided into two groups: ASRS+ with ADHD characteristics ( n = 43) and ASRS− with low/no ADHD characteristics ( n = 144). Groups were compared for AUD relapse risk at the start of treatment (baseline) and before hospital discharge using the multidimensional Alcohol Relapse Risk Scale (ARRS). The change in relapse risk during hospitalization was also compared by assessment of the interaction between groups (ASRS+ vs. ASRS−) and time (at discharge vs. baseline).
Results
The total ARRS score and dimension subscores for stimulus‐induced vulnerability and emotionality problems were significantly higher in the ASRS+ group at baseline and before discharge compared to the ASRS− group. There was a significant group × time interaction indicating less improvement of stimulus‐induced vulnerability during inpatient treatment among the ASRS+ group compared to the ASRS− group.
Conclusions
Our findings suggest that AUD patients with ADHD characteristics have a higher risk of relapse both at baseline and after inpatient treatment. Stimulus‐induced vulnerability to relapse is less likely to improve with treatment in patients with ADHD characteristics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Liaison Psychiatry and Psycho-Oncology Unit, Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Narimasu Kosei Hospital, Tokyo, Japan.
- Department of Psychiatry and Behavioral Sciences, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.
- Jiyu Clinic, Tokyo, Japan.
- Center for Brain Integration Research, Tokyo Medical and Dental University, Tokyo, Japan.
ORCID-Profile: Takahiro Kawata
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Kawata, T., Sugihara, G., Kakibuchi, Y., Tomitaka, M., Miyajima, M., Matsushima, E., Takeuchi, T., & Takahashi, H. (2023). Attention‐deficit hyperactivity symptoms and risk of alcohol use relapse. Neuropsychopharmacology Reports, 43(1), 103-111. https://doi.org/10.1002/npr2.12312
Vancouver
Kawata T, Sugihara G, Kakibuchi Y, Tomitaka M, Miyajima M, Matsushima E, et al. Attention‐deficit hyperactivity symptoms and risk of alcohol use relapse. Neuropsychopharmacology Reports. 2023;43(1):103-111. doi:10.1002/npr2.12312
BibTeX
@article{Kawata2023,
author = {Kawata, Takahiro and Sugihara, Genichi and Kakibuchi, Yoichi and Tomitaka, Midori and Miyajima, Miho and Matsushima, Eisuke and Takeuchi, Takashi and Takahashi, Hidehiko},
title = {Attention‐deficit hyperactivity symptoms and risk of alcohol use relapse},
journal = {Neuropsychopharmacology Reports},
year = {2023},
volume = {43},
number = {1},
pages = {103--111},
doi = {10.1002/npr2.12312}
}
EUVIMED